The cologne stroke experience:: Safety and outcome in 450 patients treated with intravenous thrombolysis

被引:46
作者
Sobesky, Jan
Frackowiak, Monika
Weber, Olivier Zaro
Hahn, Moritz
Moeller-Hartmann, Walter
Rudolf, Jobst
Neveling, Michael
Grond, Martin
Schmulling, Susanne
Jacobs, Andreas
Heiss, Wolf-Dieter
机构
[1] Univ Cologne, Dept Neurol, Max Planck Inst Neurol Res, D-50924 Cologne, Germany
[2] Univ Cologne, Dept Diagnost Radiol, Cologne, Germany
[3] Univ Cologne, Dept Med Stat, Cologne, Germany
关键词
intravenous thrombolysis; modified Rankin scale; functional independence; stroke;
D O I
10.1159/000103117
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Predictors of outcome and safety in intravenous thrombolysis within 3 h in clinical routine is a matter of ongoing debate. Available reports contain small patient numbers or summarize heterogeneous multicenter data. Methods: Four hundred and fifty patients received intravenous thrombolysis within 3 h after stroke. Pretreatment NIHSS score and detailed medical history were analyzed. Noncontrast CT was performed before thrombolysis, 24-36 h later and in case of clinical deterioration. Symptomatic intracranial hemorrhage (SICH; any bleeding with an NIHSS increase of >= 4 points) and clinical outcome (modified Rankin Scale, mRS) after 3 months were recorded. Logistic regression identified parameters predictive of independence (mRS 0 - 2) and SICH. Results: Median onset to admission, door to needle and onset to treatment time was 75, 50 and 135 min, respectively. Direct presentation by emergency service (64%) was the fastest way of referral. Median pretreatment NIHSS was 11 points. Independence (mRS 0-2) was reached by 53%. Mortality was 11% (7% intracerebral, 4% extracerebral complications). Logistic regression identified low NIHSS, low age and absent diabetes as predictors of independence. Overall hemorrhagic complications and SICH were found in 18 and 4% of the patients, respectively. Extracerebral bleeding complications and allergic reactions were found in 3 and 1%, respectively. Conclusion: This largest single center report presents a sample in the range of the 3 h rt-PA cohort of all randomized controlled trials. Outcome was comparable to randomized studies with a higher rate of independence and a lower rate of mortality and SICH. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:56 / 65
页数:10
相关论文
共 28 条
  • [1] Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study
    Albers, GW
    Bates, VE
    Clark, WM
    Bell, R
    Verro, P
    Hamilton, SA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09): : 1145 - 1150
  • [2] Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial
    Clark, WM
    Wissman, S
    Albers, GW
    Jhamandas, JH
    Madden, KP
    Hamilton, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2019 - 2026
  • [3] Thrombolysis in stroke patients aged 80 years and older:: Swiss survey of IV thrombolysis
    Engelter, ST
    Reichhart, M
    Sekoranja, L
    Georgiadis, D
    Baumann, A
    Weder, B
    Müller, F
    Lüthy, R
    Arnold, M
    Michel, P
    Mattle, HP
    Tettenborn, B
    Hungerbühler, HJ
    Baumgartner, RW
    Sztajzel, R
    Bogousslavsky, J
    Lyrer, PA
    [J]. NEUROLOGY, 2005, 65 (11) : 1795 - 1798
  • [4] Early intravenous thrombolysis for acute ischemic stroke in a community-based approach
    Grond, M
    Stenzel, C
    Schmülling, S
    Rudolf, J
    Neveling, M
    Lechleuthner, A
    Schneweis, S
    Heiss, WD
    [J]. STROKE, 1998, 29 (08) : 1544 - 1549
  • [5] Intravenous tissue-type plasminogen activator therapy for ischemic stroke - Houston experience 1996 to 2000
    Grotta, JC
    Burgin, WS
    El-Mitwalli, A
    Long, M
    Campbell, M
    Morgenstern, LB
    Malkoff, M
    Alexandrov, AV
    [J]. ARCHIVES OF NEUROLOGY, 2001, 58 (12) : 2009 - 2013
  • [6] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
    Hacke, W
    Kaste, M
    Fieschi, C
    von Kummer, R
    Davalos, A
    Meier, D
    Larrue, V
    Bluhmki, E
    Davis, S
    Donnan, G
    Schneider, D
    Diez-Tejedor, E
    Trouillas, P
    [J]. LANCET, 1998, 352 (9136) : 1245 - 1251
  • [7] HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
  • [8] Hacke W, 2004, LANCET, V363, P768
  • [9] HILL MD, 2000, CMAJ, V172, P1307
  • [10] Diabetes: Impact on stroke risk and poststroke recovery
    Kissela, Brett
    Air, Ellen
    [J]. SEMINARS IN NEUROLOGY, 2006, 26 (01) : 100 - 107